PURPOSE: Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. We investigated the ability of lapatinib to reach therapeutic concentrations in the CNS following (14)C-lapatinib administration (100 mg/kg p.o. or 10 mg/kg, i.v.) to mice with MDA-MD-231-BR-HER2 brain metastases of breast cancer. METHODS: Drug concentrations were determined at differing times after administration by quantitative autoradiography and chromatography. RESULTS: (14)C-Lapatinib concentration varied among brain metastases and correlated with altered blood-tumor barrier permeability. On average, brain metastasis concentration was 7-9-fold greater than surrounding brain tissue at 2 and 12 h after oral administration. However, average lapatinib concentration in brain metastases was still only 10-20% of those in peripheral metastases. Only in a subset of brain lesions (17%) did lapatinib concentration approach that of systemic metastases. No evidence was found of lapatinib resistance in tumor cells cultured ex vivo from treated brains. CONCLUSIONS: Results show that lapatinib distribution to brain metastases of breast cancer is partially restricted and blood-tumor barrier permeability is a key component of lapatinib therapeutic efficacy which varies between tumors.
PURPOSE:Lapatinib, a small molecule EGFR/HER2 inhibitor, partially inhibits the outgrowth of HER2+ brain metastases in preclinical models and in a subset of CNS lesions in clinical trials of HER2+ breast cancer. We investigated the ability of lapatinib to reach therapeutic concentrations in the CNS following (14)C-lapatinib administration (100 mg/kg p.o. or 10 mg/kg, i.v.) to mice with MDA-MD-231-BR-HER2brain metastases of breast cancer. METHODS: Drug concentrations were determined at differing times after administration by quantitative autoradiography and chromatography. RESULTS: (14)C-Lapatinib concentration varied among brain metastases and correlated with altered blood-tumor barrier permeability. On average, brain metastasis concentration was 7-9-fold greater than surrounding brain tissue at 2 and 12 h after oral administration. However, average lapatinib concentration in brain metastases was still only 10-20% of those in peripheral metastases. Only in a subset of brain lesions (17%) did lapatinib concentration approach that of systemic metastases. No evidence was found of lapatinib resistance in tumor cells cultured ex vivo from treated brains. CONCLUSIONS: Results show that lapatinib distribution to brain metastases of breast cancer is partially restricted and blood-tumor barrier permeability is a key component of lapatinib therapeutic efficacy which varies between tumors.
Authors: Scott G Summerfield; Kevin Read; David J Begley; Tanja Obradovic; Ismael J Hidalgo; Sara Coggon; Ann V Lewis; Rod A Porter; Phil Jeffrey Journal: J Pharmacol Exp Ther Date: 2007-04-03 Impact factor: 4.030
Authors: D W Rusnak; K Affleck; S G Cockerill; C Stubberfield; R Harris; M Page; K J Smith; S B Guntrip; M C Carter; R J Shaw; A Jowett; J Stables; P Topley; E R Wood; P S Brignola; S H Kadwell; B R Reep; R J Mullin; K J Alligood; B R Keith; R M Crosby; D M Murray; W B Knight; T M Gilmer; K Lackey Journal: Cancer Res Date: 2001-10-01 Impact factor: 12.701
Authors: Manabu Kinoshita; Nathan McDannold; Ferenc A Jolesz; Kullervo Hynynen Journal: Proc Natl Acad Sci U S A Date: 2006-07-25 Impact factor: 11.205
Authors: Shizhen Emily Wang; Archana Narasanna; Marianela Perez-Torres; Bin Xiang; Frederick Y Wu; Seungchan Yang; Graham Carpenter; Adi F Gazdar; Senthil K Muthuswamy; Carlos L Arteaga Journal: Cancer Cell Date: 2006-07 Impact factor: 31.743
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Diane Palmieri; Julie L Bronder; Jeanne M Herring; Toshiyuki Yoneda; Robert J Weil; Andreas M Stark; Raffael Kurek; Eleazar Vega-Valle; Lionel Feigenbaum; Douglas Halverson; Alexander O Vortmeyer; Seth M Steinberg; Kenneth Aldape; Patricia S Steeg Journal: Cancer Res Date: 2007-05-01 Impact factor: 12.701
Authors: Major Gooyit; Wei Song; Kiran V Mahasenan; Katerina Lichtenwalter; Mark A Suckow; Valerie A Schroeder; William R Wolter; Shahriar Mobashery; Mayland Chang Journal: J Med Chem Date: 2013-10-08 Impact factor: 7.446
Authors: Rachel A Freedman; Rebecca S Gelman; Nathalie Y R Agar; Sandro Santagata; Elizabeth C Randall; Begoña Gimenez-Cassina Lopez; Roisin M Connolly; Ian F Dunn; Catherine H Van Poznak; Carey K Anders; Michelle E Melisko; Kelly Silvestri; Christine M Cotter; Kathryn P Componeschi; Juan M Marte; Beverly Moy; Kimberly L Blackwell; Shannon L Puhalla; Nuhad Ibrahim; Timothy J Moynihan; Julie Nangia; Nadine Tung; Robyn Burns; Mothaffar F Rimawi; Ian E Krop; Antonio C Wolff; Eric P Winer; Nancy U Lin Journal: Clin Breast Cancer Date: 2019-08-22 Impact factor: 3.225
Authors: Shannon Puhalla; William Elmquist; David Freyer; Lawrence Kleinberg; Chris Adkins; Paul Lockman; John McGregor; Leslie Muldoon; Gary Nesbit; David Peereboom; Quentin Smith; Sara Walker; Edward Neuwelt Journal: Neuro Oncol Date: 2015-05 Impact factor: 12.300
Authors: Diane Palmieri; Renata Duchnowska; Stephan Woditschka; Emily Hua; Yongzhen Qian; Wojciech Biernat; Katarzyna Sosińska-Mielcarek; Brunilde Gril; Andreas M Stark; Stephen M Hewitt; David J Liewehr; Seth M Steinberg; Jacek Jassem; Patricia S Steeg Journal: Clin Cancer Res Date: 2014-03-14 Impact factor: 12.531
Authors: L Tiffany Lyle; Paul R Lockman; Chris E Adkins; Afroz Shareef Mohammad; Emily Sechrest; Emily Hua; Diane Palmieri; David J Liewehr; Seth M Steinberg; Wojciech Kloc; Ewa Izycka-Swieszewska; Renata Duchnowska; Naema Nayyar; Priscilla K Brastianos; Patricia S Steeg; Brunilde Gril Journal: Clin Cancer Res Date: 2016-05-31 Impact factor: 12.531
Authors: Matthias A Karajannis; Geneviève Legault; Mari Hagiwara; Marc S Ballas; Krysten Brown; Annette O Nusbaum; Tsivia Hochman; Judith D Goldberg; Kevin M Koch; John G Golfinos; J Thomas Roland; Jeffrey C Allen Journal: Neuro Oncol Date: 2012-07-27 Impact factor: 12.300
Authors: Selvi Durmus; Rolf W Sparidans; Anita van Esch; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel Journal: Pharm Res Date: 2014-06-25 Impact factor: 4.200